ERASCA INC
NASDAQ: ERAS (Erasca, Inc.)
Kemas kini terakhir: 3 jam lalu14.05
0.04 (0.29%)
| Penutupan Terdahulu | 14.01 |
| Buka | 14.15 |
| Jumlah Dagangan | 2,078,145 |
| Purata Dagangan (3B) | 6,875,512 |
| Modal Pasaran | 4,369,332,736 |
| Harga / Buku (P/B) | 11.10 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.570 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 12.72% |
| Nisbah Semasa (MRQ) | 12.35 |
| Aliran Tunai Operasi (OCF TTM) | -107.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -91.89 M |
| Pulangan Atas Aset (ROA TTM) | -22.16% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Erasca, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.38 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.69% |
| % Dimiliki oleh Institusi | 84.38% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 31 Mar 2026 | 24,675,188 |
| Vivo Capital, Llc | 31 Mar 2026 | 12,151,480 |
| Siren, L.L.C. | 31 Mar 2026 | 11,244,246 |
| Arch Venture Management, Llc | 31 Mar 2026 | 7,091,557 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |